Structure of catalytic domain of Matriptase in complex with Sunflower trypsin inhibitor-1

BMC Structural Biology

Volumn 11, Issue , 2011, Pages

  Yuan, Cai ^a   Chen, Liqing ^b   Meehan, Edward J ^b   Daly, Norelle ^c   Craik, David J ^c   Huang, Mingdong ^a   Ngo, Jacky C ^d  

^a FUJIAN INSTITUTE OF RESEARCH ON THE STRUCTURE OF MATTER   (China)

^b UNIVERSITY OF ALABAMA IN HUNTSVILLE   (United States)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDINE; MATRIPTASE; RECOMBINANT PROTEIN; SUNFLOWER TRYPSIN INHIBITOR 1; TRYPSIN; TRYPSIN INHIBITOR; UNCLASSIFIED DRUG; BENZAMIDINE DERIVATIVE; CYCLOPEPTIDE; SERINE PROTEINASE; SFTI 1 PEPTIDE, SUNFLOWER; SFTI-1 PEPTIDE, SUNFLOWER; ST14 PROTEIN, HUMAN;

ARTICLE; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME ENGINEERING; NONHUMAN; PLANT SEED; SUNFLOWER; BINDING SITE; CHEMISTRY; ENZYME SPECIFICITY; METABOLISM; PROTEIN CONFORMATION; PROTEIN TERTIARY STRUCTURE;

HELIANTHUS;

BENZAMIDINES; BINDING SITES; CATALYTIC DOMAIN; PEPTIDES, CYCLIC; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SERINE ENDOPEPTIDASES; SUBSTRATE SPECIFICITY;

EID: 79959187602     PISSN: None     EISSN: 14726807     Source Type: Journal    
DOI: 10.1186/1472-6807-11-30     Document Type: Article

References (49)

1. Ovarian tumor cells express a transmembrane serine protease: a potential candidate for early diagnosis and therapeutic intervention. H Tanimoto LJ Underwood Y Wang K Shigemasa TH Parmley TJ O'Brien, Tumour Biol 2001 22 2 104 114 10.1159/000050604 11125283 (Pubitemid 32008967)
2. Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. CY Lin J Anders M Johnson QA Sang RB Dickson, J Biol Chem 1999 274 26 18231 18236 10.1074/jbc.274.26.18231 10373424
3. Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. T Takeuchi MA Shuman CS Craik, Proc Natl Acad Sci USA 1999 96 20 11054 11061 10.1073/pnas.96.20.11054 10500122 (Pubitemid 29487326)
4. Matriptase is a novel initiator of cartilage matrix degradation in osteoarthritis. JM Milner A Patel RK Davidson TE Swingler A Desilets DA Young EB Kelso ST Donell TE Cawston IM Clark,, et al. Arthritis Rheum 2010 62 7 1955 1966 20506309
5. Initiation of plasminogen activation on the surface of monocytes expressing the type II transmembrane serine protease matriptase. LM Kilpatrick RL Harris KA Owen R Bass C Ghorayeb A Bar-Or V Ellis, Blood 2006 108 8 2616 2623 10.1182/blood-2006-02-001073 16794252
6. Matriptase expression in the normal and neoplastic mast cells. MF Cheng JS Jin HW Wu PC Chiang LF Sheu HS Lee, Eur J Dermatol 2007 17 5 375 380 17673379
7. Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. K List CC Haudenschild R Szabo W Chen SM Wahl W Swaim LH Engelholm N Behrendt TH Bugge, Oncogene 2002 21 23 3765 3779 10.1038/sj.onc.1205502 12032844 (Pubitemid 34620539)
8. Matriptase inhibition by hepatocyte growth factor activator inhibitor-1 is essential for placental development. R Szabo A Molinolo K List TH Bugge, Oncogene 2007 26 11 1546 1556 10.1038/sj.onc.1209966 16983341 (Pubitemid 46398747)
9. Loss of matriptase suppression underlies spint1 mutation-associated ichthyosis and postnatal lethality. R Szabo P Kosa K List TH Bugge, Am J Pathol 2009 174 6 2015 2022 10.2353/ajpath.2009.090053 19389929
10. Hepatocyte growth factor activator inhibitor-1 (HAI-1) is essential for the integrity of basement membranes in the developing placental labyrinth. B Fan J Brennan D Grant F Peale L Rangell D Kirchhofer, Dev Biol 2007 303 1 222 230 10.1016/j.ydbio.2006.11.005 17174946 (Pubitemid 46241099)
11. Inactivation of serine protease Matriptase1a by its inhibitor Hai1 is required for epithelial integrity of the zebrafish epidermis. TJ Carney S von der Hardt C Sonntag A Amsterdam J Topczewski N Hopkins M Hammerschmidt, Development 2007 134 19 3461 3471 10.1242/dev.004556 17728346 (Pubitemid 350028365)
12. The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor. MD Oberst CA Williams RB Dickson MD Johnson CY Lin, J Biol Chem 2003 278 29 26773 26779 10.1074/jbc.M304282200 12738778 (Pubitemid 36876825)
13. Autoactivation of matriptase in vitro: requirement for biomembrane and LDL receptor domain. MS Lee IC Tseng Y Wang K Kiyomiya MD Johnson RB Dickson CY Lin, Am J Physiol Cell Physiol 2007 293 1 95 105 10.1152/ajpcell.00611.2006 17344310
14. Matriptase activation, an early cellular response to acidosis. IC Tseng H Xu FP Chou G Li AP Vazzano JP Kao MD Johnson CY Lin, J Biol Chem 2010 285 5 3261 3270 10.1074/jbc.M109.055640 19940125
15. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. SL Lee RB Dickson CY Lin, J Biol Chem 2000 275 47 36720 36725 10.1074/jbc.M007802200 10962009 (Pubitemid 32002078)
16. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. T Takeuchi JL Harris W Huang KW Yan SR Coughlin CS Craik, J Biol Chem 2000 275 34 26333 26342 10.1074/jbc.M002941200 10831593
17. Matriptase initiates activation of epidermal pro-kallikrein and disease onset in a mouse model of Netherton syndrome. K Sales A Masedunskas A Bey A Rasmussen R Weigert K List R Szabo P Overbeek T Bugge, Nat Genet 2010 42 8 676 683 10.1038/ng.629 20657595
18. Matriptase: a culprit in cancer? K List, Future Oncol 2009 5 1 97 104 10.2217/14796694.5.1.97 19243302
19. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. M Saleem VM Adhami W Zhong BJ Longley CY Lin RB Dickson S Reagan-Shaw DF Jarrard H Mukhtar, Cancer Epidemiol Biomarkers Prev 2006 15 2 217 227 10.1158/1055-9965.EPI-05-0737 16492908 (Pubitemid 43342167)
20. Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia. JW Lee S Yong Song JJ Choi SJ Lee BG Kim CS Park JH Lee CY Lin RB Dickson DS Bae, Hum Pathol 2005 36 6 626 633 10.1016/j.humpath.2005.03.003 16021568 (Pubitemid 40922568)
21. Transmembrane serine protease TADG-15 (ST14/Matriptase/MT-SP1): expression and prognostic value in ovarian cancer. H Tanimoto K Shigemasa X Tian L Gu JB Beard T Sawasaki TJ O'Brien, Br J Cancer 2005 92 2 278 283 15611789 (Pubitemid 40343141)
22. Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. K List R Szabo A Molinolo V Sriuranpong V Redeye T Murdock B Burke BS Nielsen JS Gutkind TH Bugge, Genes Dev 2005 19 16 1934 1950 10.1101/gad.1300705 16103220 (Pubitemid 41186993)
23. Membrane-type serine protease-1/matriptase induces interleukin-6 and -8 in endothelial cells by activation of protease-activated receptor-2: potential implications in atherosclerosis. I Seitz S Hess H Schulz R Eckl G Busch HP Montens R Brandl S Seidl A Schomig I Ott, Arterioscler Thromb Vasc Biol 2007 27 4 769 775 10.1161/01.ATV.0000258862.61067.14 17255532 (Pubitemid 46606705)
24. Autosomal recessive ichthyosis with hypotrichosis caused by a mutation in ST14, encoding type II transmembrane serine protease matriptase. L Basel-Vanagaite R Attia A Ishida-Yamamoto L Rainshtein D Ben Amitai R Lurie M Pasmanik-Chor M Indelman A Zvulunov S Saban,, et al. Am J Hum Genet 2007 80 3 467 477 10.1086/512487 17273967
25. Autosomal recessive ichthyosis with hypotrichosis syndrome: further delineation of the phenotype. L Avrahami S Maas M Pasmanik-Chor L Rainshtein N Magal J Smitt J van Marle M Shohat L Basel-Vanagaite, Clin Genet 2008 74 1 47 53 10.1111/j.1399-0004.2008.01006.x 18445049 (Pubitemid 351833818)
26. Ichthyosis, follicular atrophoderma, and hypotrichosis caused by mutations in ST14 is associated with impaired profilaggrin processing. T Alef S Torres I Hausser D Metze U Tursen GG Lestringant HC Hennies, J Invest Dermatol 2009 129 4 862 869 10.1038/jid.2008.311 18843291
27. Synthesis and evaluation of the sunflower derived trypsin inhibitor as a potent inhibitor of the type II transmembrane serine protease, matriptase. YQ Long SL Lee CY Lin IJ Enyedy S Wang P Li RB Dickson PP Roller, Bioorg Med Chem Lett 2001 11 18 2515 2519 10.1016/S0960-894X(01)00493-0 11549459 (Pubitemid 32823346)
28. High-resolution structure of a potent, cyclic proteinase inhibitor from sunflower seeds. S Luckett RS Garcia JJ Barker AV Konarev PR Shewry AR Clarke RL Brady, J Mol Biol 1999 290 2 525 533 10.1006/jmbi.1999.2891 10390350 (Pubitemid 29324836)
29. Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1. G Zhao C Yuan T Wind Z Huang PA Andreasen M Huang, J Struct Biol 2007 160 1 1 10 10.1016/j.jsb.2007.06.003 17692534 (Pubitemid 47405230)
30. Catalytic domain structures of MT-SP1/matriptase, a matrix-degrading transmembrane serine proteinase. R Friedrich P Fuentes-Prior E Ong G Coombs M Hunter R Oehler D Pierson R Gonzalez R Huber W Bode,, et al. J Biol Chem 2002 277 3 2160 2168 10.1074/jbc.M109830200 11696548 (Pubitemid 34968802)
31. Studies on an artificial trypsin inhibitor peptide derived from the mung bean trypsin inhibitor: chemical synthesis, refolding, and crystallographic analysis of its complex with trypsin. Y Li Q Huang S Zhang S Liu C Chi Y Tang, J Biochem 1994 116 1 18 25 7798176 (Pubitemid 24230777)
32. Structure of the trypsin-binding domain of Bowman-Birk type protease inhibitor and its interaction with trypsin. Y Tsunogae I Tanaka T Yamane J Kikkawa T Ashida C Ishikawa K Watanabe S Nakamura K Takahashi, J Biochem 1986 100 6 1637 1646 3032921 (Pubitemid 17213626)
33. Three-dimensional structure of soybean trypsin/chymotrypsin Bowman-Birk inhibitor in solution. MH Werner DE Wemmer, Biochemistry 1992 31 4 999 1010 10.1021/bi00119a008 1734975
34. Cation-pi interactions in structural biology. JP Gallivan DA Dougherty, Proc Natl Acad Sci USA 1999 96 17 9459 9464 10.1073/pnas.96.17.9459 10449714
35. Cation-pi interactions in protein-protein interfaces. PB Crowley A Golovin, Proteins 2005 59 2 231 239 10.1002/prot.20417 15726638
36. Design and synthesis of novel and potent inhibitors of the type II transmembrane serine protease, matriptase, based upon the sunflower trypsin inhibitor-1. P Li S Jiang SL Lee CY Lin MD Johnson RB Dickson CJ Michejda PP Roller, J Med Chem 2007 50 24 5976 5983 10.1021/jm0704898 17985858
37. Ligand configurational entropy and protein binding. CE Chang W Chen MK Gilson, Proc Natl Acad Sci USA 2007 104 5 1534 1539 10.1073/pnas.0610494104 17242351 (Pubitemid 46214625)
38. Design and characterization of a highly selective peptide inhibitor of the small conductance calcium-activated K+ channel, SkCa2. VG Shakkottai I Regaya H Wulff Z Fajloun H Tomita M Fathallah MD Cahalan JJ Gargus JM Sabatier KG Chandy, J Biol Chem 2001 276 46 43145 43151 10.1074/jbc.M106981200 11527975
39. Solution structures by 1H NMR of the novel cyclic trypsin inhibitor SFTI-1 from sunflower seeds and an acyclic permutant. MLJ Korsinczky HJ Schirra KJ Rosengren J West BA Condie L Otvos MA Anderson DJ Craik, J Mol Biol 2001 311 3 579 591 10.1006/jmbi.2001.4887 11493011 (Pubitemid 32816591)
40. MOLREP: an automated program for molecular replacement. A Vagin A Teplyakov, J Appl Cryst 1997 30 1022 1025 10.1107/S0021889897006766 (Pubitemid 127485985)
41. The CCP4 suite; Programs for protein crystallography. CCP4, Acta Crystallogr D Biol Crystallogr 1994 50 760 763 10.1107/S0907444994003112 15299374
42. Refinement of macromolecular structures by the maximum-likelihood method. GN Murshudov AA Vagin EJ Dodson, Acta Crystallogr D Biol Crystallogr 1997 53 Pt 3 240 255 15299926 (Pubitemid 27235885)
43. PHENIX: a comprehensive Python-based system for macromolecular structure solution. PD Adams PV Afonine G Bunkoczi VB Chen IW Davis N Echols JJ Headd L-W Hung GJ Kapral RW Grosse-Kunstleve,, et al. Acta Crystallogr D Biol Crystallogr 2010 66 2 213 221 10.1107/S0907444909052925 20124702
44. Coot: model-building tools for molecular graphics. P Emsley K Cowtan, Acta Crystallogr D Biol Crystallogr 2004 60 2126 2132 10.1107/S0907444904019158 15572765 (Pubitemid 41742764)
45. TLSMD web server for the generation of multi-group TLS models. J Painter EA Merritt, J Appl Crystallogr 2006 39 109 111 10.1107/S0021889805038987
46. PROCHECK: a program to check the stereochemical quality of protein structures. RA Laskowski MW MacArthur DS Mass JM Thornton, J Appl Crystallogr 1993 26 283 291 10.1107/S0021889892009944
47. The PyMol Molecular Graphics system. WL DeLano, DeLano scientific, San Carlos, CA, USA 2002
48. Electrostatics of nanosystems: Application to microtubules and the ribosome. NA Baker D Sept S Joseph MJ Holst JA McCammon, Proc Natl Acad Sci USA 2001 98 10037 10041 10.1073/pnas.181342398 11517324 (Pubitemid 32802969)
49. Mutation of surface residues to promote crystallization of activated factor XI as a complex with benzamidine: an essential step for the iterative structure-based design of factor XI inhibitors. L Jin P Pandey RE Babine DT Weaver SS Abdel-Meguid JE Strickler, Acta Crystallogr D Biol Crystallogr 2005 61 1418 1425 10.1107/S0907444905024340 16204896 (Pubitemid 43943143)